PatternsRadar
Sign in

PANACEABIOPanacea Biotec Limited

NSE
Full chart
363.20INR+12.95 (+3.70%)Close · 6 Oct 2026
13 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹2,225 CrMarket cap
—P/E (TTM)
46.1%Delivery

Filings & corporate actions

78 results filed
CSV
Next results · Q2 FY27
Expected 11 Nov 2026 – 16 Nov 2026
Estimate: filed 42–47 days after quarter end, last 5 times
2026
  • 13 AugresultsResults · Q1 FY27 · consolidated and standalone-4.3%NSE
  • 21 JulshareholdingShareholding · 30 Jun 2026-10.0%NSE
  • 31 MayresultsResults · Q4 FY26 · consolidated and standalone-3.6%NSE
  • 21 AprshareholdingShareholding · 31 Mar 2026-1.0%NSE
  • 11 FebresultsResults · Q3 FY26 · consolidated and standalone+0.7%NSE
  • 9 JanshareholdingShareholding · 31 Dec 2025-6.0%NSE

Reaction to results · all yearsrose on day 0 in 23 of 78 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2713 Aug 2026-4.3%-0.7%-4.0%1.1×
Q4 FY2631 May 2026-3.6%+33.9%+37.1%2.0×
Q3 FY2611 Feb 2026+0.7%-2.4%-8.3%0.5×
Q2 FY2614 Nov 2025-2.5%-13.4%-10.7%2.0×
Q1 FY2614 Aug 2025-2.8%-4.0%+3.4%0.9×
Q4 FY2530 May 2025-5.0%-14.9%-19.6%1.1×
Q3 FY2514 Feb 2025+2.2%-4.0%+28.4%0.5×
Q2 FY2514 Nov 2024+5.0%+25.1%+42.3%0.7×
Q1 FY2514 Aug 2024+0.3%+21.8%+93.5%1.5×
Q4 FY2430 May 2024-1.2%-2.9%+1.7%0.9×
Q3 FY2414 Feb 2024-0.2%+6.7%-11.2%0.7×
Q2 FY2411 Nov 2023+1.3%-2.6%+5.9%0.3×
Q1 FY2412 Aug 2023-4.4%+16.1%-4.7%2.6×
Q4 FY2331 May 2023-1.1%+2.9%+6.4%1.0×
Q3 FY2315 Feb 2023-1.9%-8.3%-14.0%0.9×
Q2 FY2316 Nov 2022-1.4%-1.9%-0.8%0.6×
Q1 FY2310 Aug 2022-6.4%-1.0%+0.7%2.0×
Q4 FY2219 May 2022+4.8%-11.2%-14.0%12.3×
Q3 FY2215 Feb 2022-1.5%+3.7%-6.9%0.4×
Q2 FY2213 Nov 2021-4.8%-16.4%-0.6%1.7×
Q1 FY2224 Jul 2021-5.0%-11.3%-16.7%1.1×
Q4 FY213 Jun 2021-2.2%-1.1%-5.6%0.4×
Q3 FY2112 Feb 2021-5.2%-8.8%-14.3%0.9×
Q2 FY2112 Nov 2020-1.5%+6.0%+26.4%1.1×
Q1 FY214 Sept 2020-2.4%+3.4%0.0%0.5×
Q4 FY2030 Jun 2020-1.9%-4.4%-2.2%0.2×
Q3 FY2015 Feb 2020-4.0%-9.7%-18.6%1.8×
Q2 FY2015 Nov 2019+5.0%+6.5%-6.8%1.1×
Q1 FY2013 Aug 2019-2.4%-19.3%0.0%0.4×
Q4 FY1931 May 2019-2.9%-14.3%-18.4%0.7×
Q3 FY1928 Feb 2019+1.5%-2.6%-1.3%3.3×
Q2 FY1928 Nov 2018-2.0%-8.2%-0.5%1.0×
Q1 FY1931 Aug 2018-1.1%-1.0%-31.5%2.3×
Q4 FY1822 Jun 2018-5.5%-14.2%-16.0%0.8×
Q3 FY1821 Feb 20180.0%-6.8%-19.1%0.3×
Q2 FY1822 Nov 2017+2.3%+10.7%-7.1%1.2×
Q1 FY1820 Sept 2017-1.6%-10.8%-0.1%0.2×
Q4 FY178 Jun 2017-1.6%-5.1%-4.5%0.8×
Q3 FY1715 Feb 2017-15.3%+0.2%+2.3%1.0×
Q2 FY1718 Nov 2016+3.0%+7.7%+14.6%1.9×
Q1 FY1715 Sept 2016-1.8%-3.1%-0.6%0.3×
Q4 FY1629 May 2016+19.4%+42.6%+32.8%129.9×
Q3 FY1613 Feb 2016+3.8%+4.1%+9.1%0.4×
Q2 FY166 Nov 2015-3.0%+2.4%+2.3%0.5×
Q1 FY1614 Aug 2015+0.5%-7.9%-4.7%0.6×
Q4 FY153 Jun 2015-4.2%-5.0%-6.0%0.3×
Q3 FY1519 Feb 2015-0.1%+2.7%-7.9%0.4×
Q2 FY155 Nov 2014+0.3%-3.0%-3.8%1.9×
Q1 FY158 Aug 2014-2.7%-0.3%+3.9%0.3×
Q4 FY1431 May 2014-2.2%0.0%+4.2%0.2×
Q3 FY1420 Feb 2014-2.4%-2.3%-2.4%0.7×
Q2 FY1419 Nov 2013-4.3%-7.2%-7.1%0.9×
Q1 FY1412 Aug 2013-1.5%-8.9%+22.7%0.9×
Q4 FY1310 Jun 2013-3.6%+39.6%+18.8%0.5×
Q3 FY1312 Feb 2013-1.6%+15.3%+16.6%0.2×
Q2 FY1310 Nov 2012+1.6%+2.3%+7.5%0.4×
Q1 FY1310 Aug 2012+0.6%+2.4%+46.1%1.0×
Q4 FY1221 May 2012-0.4%-1.0%+11.4%0.9×
Q3 FY1213 Feb 2012-0.4%-2.8%-12.7%0.9×
Q2 FY1221 Oct 2011-10.5%-4.6%-17.3%48.6×
Q1 FY1227 Jul 2011-6.4%-2.4%-19.1%2.5×
Q4 FY1113 May 2011-2.8%-4.4%-9.5%2.2×
Q3 FY1128 Jan 2011+6.2%+1.3%-2.7%3.2×
Q2 FY119 Nov 2010-0.2%-8.3%-17.9%1.5×
Q1 FY1120 Jul 2010+1.4%-3.2%-5.0%3.6×
Q4 FY107 May 2010-14.6%-23.1%-26.3%12.0×
Q3 FY101 Feb 2010-1.6%-8.8%-15.4%0.1×
Q2 FY1029 Oct 2009+0.9%-11.0%+11.7%2.1×
Q1 FY1030 Jul 2009-5.0%-0.3%+18.7%0.8×
Q4 FY0927 May 2009+4.6%+33.5%+12.4%2.9×
Q3 FY0929 Jan 2009-4.9%+5.6%+0.9%0.5×
Q2 FY093 Nov 2008+4.1%+14.2%-12.8%0.8×
Q1 FY0929 Jul 2008-0.7%+0.1%-4.2%1.0×
Q4 FY0826 Jun 2008-8.6%-8.2%-10.3%0.6×
Q3 FY0824 Jan 2008+0.5%-3.5%-12.9%0.4×
Q2 FY0823 Oct 2007-0.1%-4.7%-10.0%1.3×
Q1 FY0824 Jul 2007-1.8%-3.8%-10.0%1.6×
Q4 FY0714 Jun 2007+2.3%+1.0%-1.3%1.3×
Average-1.4%-0.2%+0.1%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+19.7%
Profit YoY-44.4%
Interest cost YoY+64.6%
Revenue QoQ+19.7%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+11.0%+12.0%+1.3%+1.5%+3.4%—
Profit——————

Key data

CSV
Open351.10
Day range349.20 – 364.75
52-week range292.40 – 647.00
From 52w high-43.9%
RSI (14)41.3
ATR (14)15.27
Volume66.8K
Avg volume (20D)88.7K
Rel volume0.75×
Volatility (1Y)54.1%
Turnover₹2.4Cr
SMA 50 / 200393.89 / 402.33

Delivery percentage

Latest · 6 Oct 202646.1%
20-day avg52.0%
1-year avg44.3%
Percentile (own history)30th
Range4.5–100.0%
Sessions1,731

Over the last 20 sessions PANACEABIO settled 52.0% of its traded quantity, which is above average for an NSE equity. Its one-year average is 44.3%, so recent sessions are running 7.7 points higher than usual. The latest session ranks higher than 30% of the 1,731 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+3.70%-0.89%-6.64%-32.54%+12.31%-10.24%

Valuation

CSV
Market cap₹2,225 Cr
P/E (TTM)—
EPS (TTM)-1.46
Shares outstanding6.13Cr
Listed17 Apr 1996

Ownership

CSV
Promoter72.48%
Promoter Δ QoQ0.00 pp
Public27.52%
FII2.31%
DII2.25%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)141.1165.2166.8199.6
YoY chg-4.2%+1.0%+25.8%+19.7%
Net profit (₹ Cr)(14.0)3.9(1.0)2.2
YoY chg-397.5%-12.4%—-44.4%
Net margin-9.9%2.4%-0.6%1.1%
EPS-2.270.650.080.38

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 72.48% · public 27.52%
30 Sept 2021: promoter 73.59%31 Dec 2021: promoter 73.59%31 Mar 2022: promoter 73.59%30 Jun 2022: promoter 73.59%30 Sept 2022: promoter 73.59%31 Dec 2022: promoter 73.59%31 Mar 2023: promoter 73.59%30 Jun 2023: promoter 73.59%30 Sept 2023: promoter 73.59%31 Dec 2023: promoter 73.59%31 Mar 2024: promoter 73.59%30 Jun 2024: promoter 73.46%30 Sept 2024: promoter 72.87%31 Dec 2024: promoter 72.49%31 Mar 2025: promoter 72.48%30 Jun 2025: promoter 72.48%30 Sept 2025: promoter 72.48%31 Dec 2025: promoter 72.48%31 Mar 2026: promoter 72.48%30 Jun 2026: promoter 72.48%
2021-092026-06
  • Promoter
  • Public and others
Promoter
72.48%
Public
27.52%
Promoter change
0.00 pp
Filed
21 Jul 2026
FII
2.31%
DII
2.25%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations143.0150.5136.5115.7147.4163.5132.5166.7141.1165.2166.8199.6
Other income3.25.710.83.84.73.68.65.76.42.32.64.2
Total income146.3156.2147.3119.5152.0167.1141.1172.4147.5167.5169.3203.8
Total expenses156.8160.6152.1139.3150.0165.5168.9177.1169.4163.8173.3203.0
└ Finance costs0.90.90.80.91.01.01.00.92.11.91.21.2
└ Depreciation9.39.18.88.78.79.08.48.48.38.57.97.9
Profit before tax(7.8)(1.7)(2.1)(17.1)4.84.4(0.0)6.6(19.2)6.5(1.3)3.6
Tax expense0.50.6(0.1)(1.2)0.1(0.1)2.02.6(5.2)2.6(0.3)1.4
Net profit(8.3)(2.2)(2.0)(15.9)4.74.4(2.0)4.0(14.0)3.9(1.0)2.2
EPS-1.35-0.37-0.23-2.590.770.74-0.310.66-2.270.650.080.38
Net margin-5.80%-1.46%-1.46%-13.72%3.20%2.72%-1.50%2.38%-9.93%2.35%-0.60%1.10%
PBT margin-5.44%-1.10%-1.55%-14.73%3.23%2.68%-0.03%3.94%-13.58%3.93%-0.75%1.79%
Tax rate————1.05%-1.37%—39.63%—40.06%—38.38%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 13 Aug 2026.

PANACEABIO at a glance

  • PANACEABIO closed at ₹363.2 on 6 Oct 2026, +3.70% on the day, -10.2% over one year, 43.9% below its 52-week high of ₹647.
  • Delivery was 46.1% of traded quantity on 6 Oct 2026, the 30th percentile of its own 1,731 sessions with a reading (20-session average 52.0%, 1-year average 44.3%).
  • Market capitalisation is ₹2,225 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-1.46).
  • Q1 FY27 results (consolidated, filed 13 Aug 2026): revenue ₹200 crore (+19.7% year on year), net profit ₹2 crore (-44.4%); the price moved -4.3% on the first session after.
  • Promoters held 72.48% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 11 Nov 2026 and 16 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE922B01023
SeriesEQ
Listed17 Apr 1996
History from18 Apr 1996
Sessions7,210

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE